No Data
No Data
No Data
No Data
No Data
HC Wainwright & Co. : The BioLine Rx (BLRX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $21.00.
HC Wainwright & Co. : The BioLine Rx (BLRX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $21.00.
Zhitong FinanceApr 18 01:40
Buy Rating on Bioline RX Ltd for Breakthrough Stem Cell Mobilization and Enhanced Apheresis Efficiency
TipRanksApr 17 23:05
BioLineRx Announces Poster Presentation On Apheresis Center Efficiency And CXCR4 Antagonists Including APHEXDA At ASFA 2024 Annual Meeting Apr. 17-19
BioLineRx Announces Poster Presentation On Apheresis Center Efficiency And CXCR4 Antagonists Including APHEXDA At ASFA 2024 Annual Meeting Apr. 17-19
BenzingaApr 17 19:02
BioLineRx Has Drawn-down The Second Tranche Of $20M Under Its Previously Announced $40M Non-Dilutive Debt Financing Agreement With Funds And Accounts Managed By Blackrock
BioLineRx Has Drawn-down The Second Tranche Of $20M Under Its Previously Announced $40M Non-Dilutive Debt Financing Agreement With Funds And Accounts Managed By Blackrock
BenzingaApr 10 19:14
BioLineRx to Raise $6M Through a Direct Offering
Seeking AlphaApr 1 21:14
BioLineRx Announces $6M Registered Direct Offering Of 7.5M ADS And Warrants To Purchase Up To An Aggregate Of 7.5M ADSs, At A Combined Purchase Price Of $0.80 Per ADS And Accompanying Warrant
BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced t
BenzingaApr 1 21:02
No Data
No Data